Member Info for Energyshares

“ There just aren't that many out there.”

“But we would love to find one with 3 substantial platforms and a bonus if they dad a diagnostics division.”

:):):):):):)

Succeeded where others have failed.

100% better than doxorubicin on the market now.

Red Devil now tamed..
GLA

Not just Chemo Pre/Cision is going after but other drugs.

More markets to go at.

The very significant reduction in the usual toxicities, plus the observed release of doxorubicin at significant levels in the tumour tissue, show that the pre|CISIONTM platform has the potential to significantly improve the safety and tolerability of chemotherapies, and other drugs, by targeting their release to the tumour.

Little Avacta will have Big Pharma all over this.

Relaxed and chilled :):):)

Not just Pre/Cision but this brings out the real value driver TMac

Welcome back poirot ;)

5hrs extra on a chemo session for a patient requesting a cold cap to try and stop hair loss what a a lot of time suffering and massive saving for the NHS

THANK YOU Avacta it’s got to be Sir Dr Smith now

Typical toxicities include alopecia, myelosuppression, nausea, vomiting, mucositis and cardiotoxicity. Importantly, even at the highest dosing levels in cohort 4, equivalent to more than double the normal dose of doxorubicin, the typical drug-related cardiotoxicity of doxorubicin was not observed.

Designating an Orphan Product: Drugs and Biological Products

Supporting the development and evaluation of new treatments for rare diseases is a key priority for the FDA. The FDA has authority to grant orphan drug designation to a drug or biological product to prevent, diagnose or treat a rare disease or condition. Orphan drug designation qualifies sponsors for incentives including: 
* Tax credits for qualified clinical trials
* Exemption from user fees 
* Potential seven years of market exclusivity after approval
Sponsors seeking orphan drug designation for a drug must submit a request for designation to the agency. Sponsors requesting designation of the same drug for the same rare disease or condition as a previously designated product must submit their own data and information to support their designation request. Orphan drug designation is a separate process from seeking approval or licensing. Drugs for rare diseases go through the same rigorous scientific review process as any other drug for approval or licensing. 

“key priority for the FDA.”

“Sponsors requesting designation of the same drug for the same rare disease or condition as a previously designated product must submit their own data and information to support their designation request. “

So is AVA6000 better than any other Doxorubicin drug that’s on the market.

“Orphan drug designation is a separate process from seeking approval or licensing. Drugs for rare diseases go through the same rigorous scientific review process as any other drug for approval or licensing.”

“It works”

Board Room in Wetherby all major Pharma representatives sitting around the table.
Big Al walks in:

“Morning All”

Then pulls out his Sword

“Brothers….sisters….today, a great legacy rests upon your shoulders,” he says.
“Because here we make more than just drugs...we make proper proper drugs”

“Drugs that bring a tear to your eye and warmth to your soul.

“So go out there and do it for each other, do it for yourselves – but most of all, do it for Yorkshire.”

RNS then delivered :)

Yep paint your wagon..

Course you did ….

Derek,
Cancel the world cruise and go around the Med.

Give the BOD some credit for the position they have got Avacta to.

GLA

Touk
I think you have overstretched yourself.
Cash out a few shares and chill.

It’s a cancer trial FFS

Lots going on in background

Rah after all yours and Tom’s research don’t bother answering Derek ,if he can’t be bothered reading and researching.

NDN
Wynbore
Mumbo

Yes please

Great find Tom the bomb ;):):)

Must of missed that,
I thought you jumped ship…

Why did you change your user name
Mr Adventurous ?

Mumbo trying to get in cheap to cover your big losses on AGL. :):):):)

K nob